Speaking at the World Health Organization's executive board meeting on October 6, the agency's Director-General Tedros Adhanom Ghebreyesus said "there is hope" that a vaccine against COVID-19 may be ready by the end of this year. During his closing remarks, Tedros called for solidarity a...
The COVID-19 vaccine developed by China's Sinopharm has been approved by the World Health Organization (WHO) for "emergency use." This means its safety, efficacy and quality has been checked and it can be used by the international COVAX vaccine effort. WHO Director-General Tedros...
WHO guidance on COVID-19 vaccine trial designs in the context of authorized COVID-19 vaccines and expanding global access: Ethical considerationsJerome Amir Singh a b cSonali Kochhar d eJonathan Wolff fCaesar Atuire gAnant Bhan hEzekiel Emanuel i...
The World Health Organization (WHO) validated on May 19 the CONVIDECIA COVID-19 vaccine developed by Chinese developer CanSino Biologics for emergency use, making it the third Chinese vaccine after Sinopharm and Sinovac having been certified by WHO Emergency Use Listing (EUL). The WHO said in a...
SARS-CoV-2 vaccines provide significant protection against severe illness and death from COVID-19, in addition to reducing community transmission. Emerging research has identified factors associated with vaccine uptake among adults who use drugs; however, less is known about youth and young adults who...
population were vaccinated by then. Tedros made the remarks during a visit to a partly state-owned vaccine producer in South Africa on Saturday. He said the World Trade Organization's intellectual property rights agreement on patent waivers was in place for situations like the ...
GENEVA, May 19 (Xinhua) -- The World Health Organization (WHO) validated on Thursday the CONVIDECIA COVID-19 vaccine developed by Chinese developer CanSino Biologics for emergency use, making it the third Chinese vaccine after Sinopharm and Sinopec having been certified by WHO Emergency Use Listin...
2024年3月21日,世界卫生组织更新了2023年全球疫苗市场报告。尽管报告内容更多基于2022年的内容,但对于了解当前全球疫苗市场仍有参考价值。分析均剔除了COVID-19疫苗内容,经笔者校对梳理、细节补充和简析后,主要监测结果如下: 后疫情时代疫苗生产仍高度集中
THE World Health Organisation (WHO) has cleared the controversy surrounding the Chinese Covid-19 vaccine, Sinopharm, saying countries were free to import the dr...
High efficacy and easy storage of approved vaccines Developed by the University of Oxford in partnership with the British-Swedish company AstraZeneca, the vaccine is known as ChAdOx1-S. It uses a viral vector to trigger immunity against the SARS-CoV-2, which causes the COVID-19...